Clinical Trials Browser

Phase 1/2 × OTHER × fresolimumab × Clear all

NCT02581787 2024-03-27

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Phase 1/2 Completed

28 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung